Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958458 | 0.98 | ALDH1A1 (0.56) | ALDH1A1SIGMAR1GAADRD4DRD2 | |
| SCHEMBL8290941 | 0.93 | ALDH1A1 (0.56) | ALDH1A1SIGMAR1GAADRD2HTT | |
| SCHEMBL8290942 | 0.91 | ALDH1A1 (0.55) | ALDH1A1SIGMAR1GAADRD2HTT | |
| SCHEMBL23269699 | 0.90 | ALDH1A1 (0.51) | ALDH1A1SIGMAR1DRD2KDM4ENPC1 | |
| SCHEMBL15043617 | 0.87 | ALDH1A1 (0.49) | ALDH1A1SIGMAR1NPC1LMNAMEN1 | |
| SCHEMBL16556533 | 0.87 | ALDH1A1 (0.49) | ALDH1A1SIGMAR1GAADRD4DRD2 | |
| SCHEMBL19862568 | 0.86 | SIGMAR1 (0.55) | ALDH1A1SIGMAR1NPC1MEN1KMT2A | |
| SCHEMBL12325467 | 0.84 | ALDH1A1 (0.58) | ALDH1A1SIGMAR1GAADRD4DRD2 | |
| SCHEMBL6998053 | 0.84 | ALDH1A1 (0.58) | ALDH1A1SIGMAR1DRD4DRD2KDM4E | |
| SCHEMBL20457594 | 0.84 | ALDH1A1 (0.58) | ALDH1A1DRD4DRD2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| US-9233971-B2 | Lipomacrocycles and uses thereof | AGAVE PHARMA, INCORPORATED | 2016-01-12 | — | — | US | disclosed |
| US-9233971-B2 | Lipomacrocycles and uses thereof | AGAVE PHARMA, INCORPORATED | 2016-01-12 | — | — | US | disclosed |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | AGAVE PHARMA, INCORPORATED | 2013-06-20 | — | — | US | disclosed |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | AGAVE PHARMA, INCORPORATED | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | ALDH1A1 1722/4885SIGMAR1 1011/4885GAA 319/4885 |
| US-20130156851-A1 | LIPOMACROCYCLES AND USES THEREOF | LIPC, LIPA, LIPE | ALDH1A1 2845/4885SIGMAR1 3061/4885GAA 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.